Monitor for future clinical trial results, but note that this is an early-stage study with a relatively small funding commitment. The company remains in pre-revenue development stage.
Price Chart
Executive Summary
GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota to sponsor a phase 1a/1b clinical trial of its drug candidate GTB-5550 for advanced solid tumors. The company will fund up to $3.8 million over three years for the study, which remains in the early research phase.
Key Financial Metrics
Key Facts
- GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota
- The agreement supports a phase 1a/1b clinical trial of GTB-5550 for advanced solid tumors
- GT Biopharma will fund up to $3.8 million over three years for the study
- The trial is sponsored by the University of Minnesota, not GT Biopharma
- The drug candidate GTB-5550 is in early-stage clinical development
Financial Impact
Up to $3.8 million over three years
Risk Factors
- Clinical trial may not demonstrate efficacy or safety
- High risk associated with early-stage drug development
- Limited financial resources for drug development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-015413 |
| Document: form8-k.htm | 0001493152-26-015413 |
| Document: 0001493152-26-015413-index-headers.html | 0001493152-26-015413 |
| Document: 0001493152-26-015413-index.html | 0001493152-26-015413 |
| Document: 0001493152-26-015413.txt | 0001493152-26-015413 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $9.00 $7.16 | ▲ +20.44% | ▲ +21.26% | $6.03 (+33.00%) |
Sep 3, 2026 29d ago | 8-K | $0.2524 $8.61 | ▲ +3311.25% | ▲ +3312.40% | $6.03 (+2289.07%) |
Aug 14, 2026 7w ago | Press Release | $0.2960 $0.2886 | ▲ +2.50% | ▲ +1.13% | $6.03 (−1937.16%) |
May 22, 2026 19w ago | 8-K | $0.4400 $0.4420 | ▼ −0.45% | ▲ +1.22% | $6.03 (−1270.45%) |
Apr 30, 2026 22w ago | S-1 | $0.3430 $0.3750 | ▼ −9.33% | ▼ −6.98% | $6.03 (−1658.02%) |
Apr 7, 2026 25w ago | 8-K | $0.4130 $0.3890 | ▼ −5.81% | ▼ −11.14% | $6.03 (+1360.05%) |
Mar 2, 2026 30w ago | Press Release | $0.4670 $0.4170 | ▼ −10.71% | ▼ −9.50% | $6.03 (+1191.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access